IGNT NEW NEWS

[RAZOR11]

$400M Global Market for Ingen's New Oxyview Nasal Cannula


First Quarter Sales Over $100,000

YUCAIPA, Calif., Jul 29, 2009 (GlobeNewswire via COMTEX) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing aging population and emerging markets for Home (DME), Hospital and Aviation Industries, announced today that Oxyview sales had exceeded $100,000 for the first quarter that began on June 1, 2009.
With an estimated 600M patients worldwide with chronic obstructive pulmonary disease known as "COPD", there is a high demand for the use of nasal cannulas. According to CDC, there are an estimated 23M COPD patients in the USA, and this number increases each year. These home oxygen patients use 2-3 nasal cannulas each month as a precautionary measure to avoid bacteria accumulation within the cannula. This is an estimated 800M cannulas used annually for home oxygen therapy alone. This does not include the hospital market, pediatric and infant market, and other markets inclusive of aviation and government markets such as military and VA Hospitals.

The new Oxyview Nasal Cannula applies to all markets that use nasal cannulas, and is priced at $5.75 manufacturers suggested retail price (MSRP). The dealer pricing will vary depending on purchase volume and geographic territory. This price will range from $2.00 to $2.50. The estimated market for the Oxyview Nasal Cannula at the $2.00 price is $200M annually in the USA and another $200M outside of the USA if Ingen captures 15% of the market over the next 24 months. Specifically, in the USA there is an estimated 800M cannulas used annually. Ingen's market share at 15% would be 120M, and with a $2.00 wholesale price for each Oxyview Nasal Cannula, this is an estimated $240M annually. The company gross margins are 80% to 86% since manufacturing is done in the USA and the company controls all Cost of goods sold and owns all of the intellectual property including patents, trademarks and tooling.

The marketing campaign begins in September-2009 with full color page editorials in COPD Digest and Meco Forum. These editorials regarding the new Oxyview Nasal Cannula will reach over 200,000 physicians, hospitals suppliers and major decision makers in the respiratory industry. Further, the company has recently made arrangements to attend the 2009 MEDICA Home Health Show in Germany on November 18th-2009. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.







About Ingen/Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing US and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

This news release was distributed by GlobeNewswire,

SOURCE: Ingen Technologies, Inc.

[RAZOR11]

YUCAIPA, Calif., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that the Company has signed contracts with Emergo Group, Inc. to debut the Oxyview Nasal Cannula at the world's largest healthcare exhibitions.


Related Quotes
Symbol Price Change
IGNT.PK 0.00 +0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
On November 18, 2009, Emergo Group will introduce the new Oxyview Nasal Cannula at MEDICA in Germany. MEDICA is the center of attraction for all those involved in the health care industry. More than 135,000 visitors from well over 100 countries are expected to again obtain information on all the current and future trends in in-patient and out-patient care at this annual event. With its extensive ancillary program, numerous special events, two major congresses and the largest product display in the industry, MEDICA is the hub of the medical trade.



Next, on January 25, 2010, the Emergo Group will introduce the new Oxyview Nasal Cannula at Arab Health. The Arab Health Exhibition & Congress is the largest healthcare exhibition in the Middle East, and the second largest in the world. Arab Health is viewed as a must-attend global event in the healthcare calendar. Established 35 years ago, it provides a platform for the world's leading manufacturers, wholesalers and distributors to meet the medical and scientific community in the Middle East and beyond.



Emergo is currently assisting Ingen with the development and implementation of an ISO 13485 quality management system which is a requirement for China, Japan, Canada and Europe. In addition to Europe (CE Marking), Emergo is compiling Ingen's Technical File and have been contracted to be the company's European Authorized Representative. This CE Certificate will allow Ingen to sell all European countries where CE Marking is mandatory, i.e. 31 countries to date. The CE Marking is the company's ticket to all of these countries and no other additional registrations are required accept for Italy which requires device notification for all devices placed on the Italian market.



Australia recognizes the CE Marking and therefore the approval and registration process in Australia is straightforward. Ingen is currently negotiating with an Australian distributor to market and sell the Oxyview Nasal Cannula in their country. Emergo has offices in Australia and has agreed to act as Ingen's Sponsor and register the Ingen devices with TGA. Upon receipt of the CE Marking certificate Ingen can register fairly quickly with the Australian TGA, as they recognize CE Marking.



"Ingen has interested acquirers according to the Pacific Pearl Group Inc., and company management has agreed to hold the buy-out price of no less than 10 cents a share," stated Thomas J. Neavitt, Chief Financial Officer.

[RAZOR11]

YUCAIPA, Calif., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today that Today's Senior Magazine October issue was distributed to 180,000 seniors in California and Texas combined.


Related Quotes
Symbol Price Change
IGNT.PK 0.0056 -0.0006


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
The Company has a full-page editorial and a full-page color advertisement of the new Oxyview Nasal Cannula in the October 2009 issue of Today's Senior Magazine. Today's Senior Magazine -- a senior magazine that provides important information, plus local and national products and services for people fifty and over, is one of the most read and talked about senior publications in California and Texas.



The Company is prepared to manufacture another 100,000 Oxyview Nasal Cannulas and has recently sold 50,000 Oxyview Nasal Cannulas in the past 60 days. "The patients have shown that they want the new Oxyview Nasal Cannula. Our inventory is well stocked, and we have worked out the bugs in our shipping and receiving while we maintain FDA and ISO compliance," stated Scott R. Sand, Chief Executive Officer and Chairman. Sand further stated, "Our engineering and management team are reviewing our manufacturing processes to meet projected annual inventory of 15M Oxyview Nasal Cannulas or approximately $86M in product sales. This is not unrealistic when you consider how Ingen has positioned the product, secured patents and intellectual property and has brought in the right groups to move product into the USA and globally."

[mickymoose99]

Pinnacle Digest: Looking For Opinions On Ingen Technologies' Latest News

Oct 06, 2009 (M2 PRESSWIRE via COMTEX) -- is a performance-driven online financial magazine and social network with a proven track record. After yesterday's news from Ingen Technologies, Inc. (Pink Sheets:IGNT) announcing that Yesterday's Senior Magazine October issue was distributed to 180,000 seniors in California and Texas combined, our team is inviting all shareholders to their exclusive investor controlled forum. Our staff and members have requested that all Ingen shareholders join our community and share their thoughts on the company, its development and future outlook. One of the most important aspects when we research for new investments is to understand the sentiment of the current shareholders; that is why we have released this announcement - we want to know your opinion.
Join The Ingen Investor Discussion Here:

Join PinnacleDigest.com to

Find out if Ingen makes it as a Pinnacle Featured Company,

Chat with other shareholders invested in Ingen,

Explain to our investor community what differentiates this company,

Connect with investors and professionals in the equity markets,

Meet the thousands of investors who have already become members of the Pinnacle community.

PinnacleDigest.com is an investment club comprised of over 15,000 members. We use all of our member's insight when selecting our next investment opportunity. Your membership is free - join today.

PinnacleDigest.com has no vested interest in the company mentioned herein. The company mentioned in this release has not compensated PinnacleDigest.com in any form to disseminate this release.

This source of information is from an unbiased perspective. If you wish to become a member of you will be gaining access to articles similar to this one and many other useful services we know you will find valuable. Keeping you educated and up-to-date with the market is one of our main purposes. Our approach in achieving this goal and our ability to consistently deliver high quality investment material is what defines our business model.

This news release shall not constitute an offer to sell or the solicitation of any offer to buy securities in any jurisdiction.

All material herein was prepared by Pinnacledigest.com (Pinnacle Digest) based upon information believed to be reliable. The information contained herein is not guaranteed by Pinnacledigest.com to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Pinnacledigest.com is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Pinnacledigest.com may receive compensation in cash or shares from independent third parties or from the companies mentioned.

Pinnacledigest.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Pinnacledigest.com undertakes no obligation to update such statements.

CONTACT: Pinnacle Digest WWW:

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at on the world wide web. Inquiries to .




(C)1994-2009 M2 COMMUNICATIONS
-0-